Medicines to Market Takes the Fast Lane with AI and Digital Innovation

AI and digitalization are redefining drug discovery and the medicine journey. Dive into key innovations and strategies empowering researchers and professionals in today's fast-evolving pharmaceutical landscape.
Author: Anna Codina

The Traditional Cost of Drug Discovery and Development: High Risk, High Expense

The process of discovering, developing, and bringing a new medicine to market has long been synonymous with sky-high costs, time-intensive phases, and staggering failure rates. On average, it takes 10–15 years and more than $2.5 billion to develop a single drug¹. Out of 10,000 compounds, only about 250 enter preclinical testing, 5 make it to clinical trials, and just 1 is eventually approved². Despite scientific progress, these figures have remained largely unchanged over the past decade, reflecting the inefficiencies and complexity of the traditional pharmaceutical R&D model.

A Turning Point: AI and Digitalization are Transforming Pharma

Today, we stand at the edge of a profound transformation. The widespread adoption of artificial intelligence and digital tools is beginning to disrupt every stage of drug discovery, development and even advanced manufacturing. Companies like Insilico Medicine and Exscientia, now Recursion Pharmaceutical, have used AI to identify novel drug candidates in 30 and 15-12 months respectively, a process that traditionally took 4-5 years^3,4. Pfizer employed AI and automation to accelerate COVID-19 vaccine development, reducing timelines from years to months⁵. AstraZeneca has invested in smart factories that utilize AI to create digital twins, optimizing operational flow and reducing lead times⁶. GSK has also adopted AI strategies to significantly compress drug discovery timelines⁷. Novo Nordisk is leveraging data science and AI to optimize clinical development and improve therapeutic decision-making. Published just recently was the reduction of time taken to compile regulatory documents from 12 weeks to under 10 minutes⁸.

The Data Explosion: A Goldmine for Innovation

In average we, scientists, produce today 1 million more data per unit of time that we did 40 years ago⁷. As labs embrace high-throughput experimentation and automated workflows, the amount of data generated daily has reached unprecedented levels. A single high-throughput chemistry lab can screen tens of thousands of chemical reactions per day^9,10. For example, droplet-based microfluidic platforms have the potential of running thousands of experiments per second¹¹, while digital tools can simulate billions of conditions virtually¹². We are not just creating data, we are drowning in it.

From Raw Data to Actionable Insight: The Need for Data Strategy

However, this data deluge is only valuable if harnessed properly. A robust data strategy is no longer optional—it’s essential. First, data capture and ingestion must be streamlined across instruments and platforms. Second, data standardization and normalization ensure compatibility, sharing and reuse. Third, to unlock value, data must be AI- and automation-ready, which means proper formatting, metadata tagging and enrichment¹³, and accessible infrastructure. Only then can we fully leverage AI to uncover patterns, predict outcomes, and accelerate innovation.

Conclusion

The pharmaceutical industry is at a pivotal moment. With the fusion of AI, automation, and data-driven strategies, we have the opportunity to redefine what is possible from drug discovery and development all the way to commercial manufacturing. But success depends not just on generating data—it depends on managing it intelligently. The future belongs to those who can turn data into decisions, and decisions into breakthroughs.

References

1. Mullard, A. 2019 FDA Drug Approvals. Nat. Rev. Drug Discov. 2020, 19, 79–84. https://doi.org/10.1038/d41573-020-00001-7

2. Wouters, O. J.; McKee, M.; Luyten, J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009–2018. JAMA 2020, 323 (9), 844–853. https://doi.org/10.1001/jama.2020.1166

3. Insilico Medicine. Insilico Medicine Announces First AI-Designed Drug to Advance to Phase I Trials. https://insilico.com/phase1 (accessed May 2025).

4. UK Research and Innovation. Exscientia: A Clinical Pipeline for AI-Designed Drug Candidates. https://www.ukri.org/who-we-are/how-we-are-doing/research-outcomes-and-impact/bbsrc/exscientia-a-clinical-pipeline-for-ai-designed-drug-candidates/ (accessed May 2025).

5. Pfizer. Accelerating Digital Technology for COVID-19 Vaccine Rollout. https://www.pfizer.com/news/behind-the-science/accelerating-digital-technology-covid-19-vaccine-rollout (accessed May 2025).

6. Smart Factories: Delivering more for Patients Worldwide. https://www.astrazeneca.com/content/astraz/what-science-can-do/topics/technologies/smart-factories-delivering-more-for-patients-worldwide.html# (accessed May 2025).

7. How GSK is Speeding up Drug Discovery Timelines with AI. The Tech Talks Daily Podcast, March 16, 2025. https://techblogwriter.co.uk/gsk/ (accessed May 11, 2025).

8. Novo Nordisk. Data Science and AI. Novo Nordisk, March 7, 2025. https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/cmd/2024/P10-Data-Science-and-AI.pdf (accessed May 11, 2025).
From 12 Weeks to 10 Minutes: How Novo Nordisk Accelerates Time to Value with GenAI and MongoDB, https://www.mongodb.com/solutions/customer-case-studies/novo-nordisk (accessed May25)

9. Perera, D.; Tucker, J. W.; Brahmbhatt, S.; Helal, C. J.; Chong, A.; Farrell, W.; Richardson, P.; Sach, N. W. A Platform for Automated Nanomole-Scale Reaction Screening and Micromole-Scale Synthesis in Flow. Science 2018, 359 (6374), 429-434. https://doi.org/10.1126/science.aap9112

10. Buitrago Santanilla, A.; Regalado, E. L.; Pereira, T.; Shevlin, M.; Bateman, K.; Campeau, L.-C.; Schneeweis, J.; Berritt, S.; Shi, Z.-C.; Dreher, S. D. Nanomole-Scale High-Throughput Chemistry for the Synthesis of Complex Molecules. Science 2014, 347 (6217), 49–53. https://doi.org/10.1126/science.1259203

11. Samimi, A.; Hengoju, S.; Rosenbaum, M. A. Combinatorial Sample Preparation Platform for Droplet-Based Applications in Microbiology. Sens. Actuators, B 2024, 417, 136162. https://doi.org/10.1016/j.snb.2024.136162

12. Li, S.-C.; Wang, P.-H.; Su, J.-W.; Chiang, W.-Y.; Huang, S.-H.; Lin, Y.-C.; Ou, C.-H.; Chen, C.-Y. Application of the Digital Annealer Unit in Optimizing Chemical Reaction Conditions for Enhanced Production Yields. arXiv 2024, arXiv:2407.17485 [physics.chem-ph]. https://doi.org/10.48550/arXiv.2407.17485

13. Della Corte, D.; Young, N.; Della Corte, K. A. Delivering Digital Transformation with Self-Reporting Data Assets. Lect. Notes Netw. Syst. 2021, 358, 975–985. https://doi.org/10.1007/978-3-030-89906-6_62

Real-time monitoring and hygiene practices on a pharmaceutical clean room production line

Optimizing Pharmaceutical Operations: A Deep Dive into an E2E Request-to-Result Workflow

In the pharmaceutical industry, an efficient and streamlined request-to-result workflow is essential for ensuring that processes run smoothly, and deadlines are met. However, with so many stages involved in this process, it can be challenging to identify areas that require optimization. In this blog post, we will take a deep dive into an end-to-end request-to-result workflow, exploring the different stages and common challenges that organizations face. Author: Torsten Osthus

Digitalization: Are We Seeing Results?

Digitalization leads to transformation in many dimensions and on any level. If we don't proactively shape this change, it is bound to disrupt our business models as we can see happening in many companies. That's why some companies started their digitalization strategies a decade ago, navigating challenging waters. As a digitalization expert, I'm often asked how to accelerate this journey. Author: Torsten Osthus